Tag: equity
-
Janssen Licensing Cancer Antibodies in $1.8B Deal
An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas.
-
RNA Therapeutics Company Raises $30M in First Venture Round
A company spun-off from a university biochemistry lab is raising $30 million to fund discovery of treatments targeting RNA, genetic material instructing protein production in cells.
-
Trial Underway for Inhaled Heart Rhythm Drug, Developer Raises $42M
A clinical trial is underway testing an inhaled therapy to quickly treat irregular heart rhythms, in cases where the problems occur occasionally and often resolve on their own.
-
Synthetic DNA Company Raising $70 Million in IPO
A 5 year-old enterprise developing synthetic DNA for medical and agricultural chemicals, as well as data storage, is raising $70 million in its initial public stock offering.
-
Gene Silencing Technology Licensed in $3.7B Deal
Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co
-
Start-Up Developing Immunometabolism Therapies, Gains $30M Funding
A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells.
-
Biotech in $3.7B Licensing Deal for Hepatitis-B
A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals.
-
$29.5M Funding Raised for Sinus Drug Delivery Company
A company developing a drug delivery technology to treat chronic sinus conditions is raising $29.5 million in its second venture financing round.
-
Spin-Off Company Developing New Antibiotics
A start-up enterprise in the U.K. is commercializing research from a university lab that discovered a new class of antibiotics promising to treat drug-resistant bacterial infections.
-
Virtual Reality Therapy Company Gains $5.1M in Early Funds
A company in the U.K. developing automated treatments for phobias using immersive virtual reality is raising £3.2 million ($US 5.1 million) in its first venture funding round.